Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Moderate Buy” by Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $14.25.

Several research firms recently issued reports on CRVS. Mizuho set a $13.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, October 29th. Wall Street Zen raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Barclays started coverage on Corvus Pharmaceuticals in a report on Monday, October 13th. They set an “overweight” rating and a $16.00 target price on the stock.

Corvus Pharmaceuticals Price Performance

NASDAQ:CRVS opened at $7.70 on Friday. The firm has a 50-day moving average of $8.11 and a two-hundred day moving average of $6.23. The stock has a market cap of $575.04 million, a P/E ratio of -14.53 and a beta of 0.64. Corvus Pharmaceuticals has a 1-year low of $2.54 and a 1-year high of $9.60.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. As a group, equities analysts expect that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Quarry LP bought a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth about $27,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $49,000. Russell Investments Group Ltd. acquired a new stake in Corvus Pharmaceuticals during the third quarter worth about $49,000. Sender Co & Partners Inc. bought a new position in Corvus Pharmaceuticals in the second quarter worth about $52,000. Finally, ProShare Advisors LLC acquired a new position in Corvus Pharmaceuticals in the second quarter valued at approximately $54,000. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.